Eating Disorders: FDA-Approved Drug, Off-Label Drug, and Nonpharmacological Intervention

Treatment Recommendations for Binge Eating Disorder
Student's Name
Institution
Course Code and Title
Professor's Name
Due Date
Treatment Recommendations for Binge Eating Disorder
Binge Eating Disorder (BED) is manifested by an uncontrollable compulsion to continue eating and recurring consumption of huge portions of food in a 2-hour or shorter period. The paper aims to recommend one FDA-approved drug, one off-label drug, and a non-pharmacological intervention for treating BED among children and adolescents.
FDA-Approved Drug
The Food and Drug Administration approved Vyvanse as the medication for treating BED. It is an approved oral CNS (Central Nervous System) stimulant that treats BED (Yalanis, 2022). The drug treats adolescent and child patients with hyperactivity and BED. The risk assessment to guide the Vyvanse treatment decision includes assessing the patient's risk for hypersensitivity to the drug's ingredients like amphetamine, risk of dependency and abuse, and determining whether they have cardiac disease before starting this pharmacological treatment (Yalanis, 2022). Vyvanse is effective and is more likely to enhance significant improvements in binge-eating patients than other therapies (Yalanis, 2022). It significantly reduces binging episodes, compulsions, and frequencies of eating. Nevertheless, the drug causes dry mouth, constipation, insomnia, anxiety, high heart rate, and reduced appetite.
Off-Label Drug
Since Vyvanse is the only FDA-approved medication for BED treatment, doctors can prescribe other FDA-approved drugs for the disorder even though they are not approved for the disorder's treatment or, rather, off-label drugs. Munir (2021) highlighted that antidepressants like Zoloft, an SSRI (selective serotonin reuptake inhibitor), treat BED by increasing serotonin that boosts mood and reduces appetite. The risk assessment to inform on this treatment option for treating BED includes checking the patient's history for cardiac problems. Patients not qualifying for Vyvanse treatment can benefit from Zoloft since it reduces binge eating compulsion and frequency. The...